论文部分内容阅读
作者测定了36例子宫肌瘤患者子宫组织ER、E_2和P含量及血浆E_2、P含量,观察了丙酸睾丸酮对肌瘤ER的影响。肌瘤组织ER含量37.6±4.0 fmol/mg蛋白,E_2含量401.7±92.6pg/g组织,两者均高于同一子宫正常肌组织的相应值(P<0.05)。11例肌瘤患者用丙酸睾丸酮后肌瘤组织ER含量(18.9±54 fmol/mg蛋白)较未用药组的有显著降低(P<0.05)。本实验结果表明肌瘤组织中ER及E_2水平的改变与肌瘤生长有关,丙酸睾丸酮抗肌瘤生长的机理可能与降低肌瘤组织中的ER水平有关。
The authors measured the contents of ER, E_2 and P in uterine fibroids and the contents of plasma E_2 and P in 36 patients with uterine fibroids. The effects of testosterone propionate on ER were observed. The myometrial ER was 37.6 ± 4.0 fmol / mg and the E_2 was 401.7 ± 92.6 pg / g, both of which were higher than those of the normal uterus (P <0.05). In 11 myoma patients, the ER content (18.9 ± 54 fmol / mg protein) in post-testosterone propionate tissue was significantly lower than that in the untreated group (P <0.05). The experimental results show that changes in the level of ER and E 2 fibroids and fibroids growth, testosterone propionate anti-fibroid growth mechanism may be related to the reduction of fibroids ER levels.